Racura is well out in front on the Australian bourse topic-wise today – and has had the single biggest jump price-wise – even under what has been a brutal Thursday selling day, though it’s followed closely by another healthcare company (a whole lot less positive there) and a Brazil-focused explorer.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
With more than seven million users on the HotCopper forums, every discussion and speculation can move markets – which is why getting in front of those red-hot trends is important for any trader worth their salt.
In this daily HotCopper Trends column, we break down the top three Aussie stocks through each trading day, and why they’ve drawn a daily focus intraday.
First up, Racura Oncology (ASX:RAC) has become the talk of the town over on the HotCopper forums Thursday after hitting a key milestone in Hong Kong: A third patient has now been treated with RC220 in its Phase One CPACS trial for advanced solid tumours at Queen Mary Hospital, the company said.
Most notably, and likely why Racura is getting such a buzz, is because “no phlebitis (vein inflammation) or any other adverse events were reported following dosing.” Happy news for the patient and shareholders alike.
The dosage success has helped RAC dodge what can only be described as a bloody day on the Australian bourse (down over -1.5% right now). The Oz biopharma company is up to $2.91/share, after a +23.9% hike.
Elsewhere in the top-trenders, EV Resources (ASX:EVR) got chins wagging after securing a restructured agreement to acquire the Tecomatlán processing plant.
This long-mooted acquisition plan will now allow the explorer to build a fast-tracked pathway to near-term antimony production in Puebla, Mexico. The deal’s built around several milestone-based payments.
To lunchtime, EVR has been +14% stronger.
(To note, too, EV Resources is a current client with The Market Link.)
Finally, HotCopper users found solace in Immutep (ASX:IMM), and its mid-Week 12 performance after it reported positive progress from its Phase I clinical trial for LAG-3 agonist therapy for autoimmune diseases.
The news earned Immutep a +6% bump today, but the stock’s still largely reeling from a near-90% nosedive last Friday that returned it to penny stock status.
Shares tumbled by -89% in a single session last week, wiping out most of the company’s US$411 million market value, and leaving shellshocked holders wondering what may have happened. Late today, IMM is 5.5cps.
That’s Thursday’s HotCopper Market Trends, I’m Isaac McIntyre – see you for close.
Join the discussion. See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.